{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-068503","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.993910+00:00","generated_at":"2026-06-01T06:21:07.161555+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M","bullets":["Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.","Total upfront and milestone payments to Alphamab up to $615.5 million plus tiered sales royalties.","ArriVent gains exclusive rights to develop and commercialize ADCs outside greater China; Alphamab retains greater China rights.","Deal leverages Alphamab's proprietary linker-payload platform and glycan-conjugation technology.","ArriVent CEO Bing Yao cites potential to add multiple innovative ADC programs to pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-068503","json":"https://secwatch.observer/filing/0001104659-24-068503.json","markdown":"https://secwatch.observer/filing/0001104659-24-068503.md","text":"https://secwatch.observer/filing/0001104659-24-068503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/0001104659-24-068503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/tm2416477d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:21:07.161555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}